Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2007-2008 (IM)
2007-000752-14Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of inactivated influenza vaccine (split virion) in influenza (2 arms), sponsored by Sanofi. Primary endpoints: Immunogenicity compliance per CHMP Note for Guidance CPMP/BWP/214/96 and Safety of the inactivated, split-virion influenza vaccine. Started Mar 2007; status: completed.
02
Drugs
inactivated influenza vaccine (split virion)
03
Conditions
influenza
Beyond the preview
Go deeper on 2007-000752-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000752-14.